Cardiovascular diseases

On arteriosclerosis and cholesterol

New content coming soon…


Chelation therapy

EDTA-chelation therapy is a very safe, detoxifying therapy whereby a synthetic amino acid (EDTA or ethylene diamine-tetra-acetate) is being administered intravenously. This amino acid has the property of eagerly bonding to metals and minerals. This bond is called chelate. Especially heavy metals (lead, cadmium and mercury) have a strong affinity with EDTA and form strong bonds with it.

In the forties and fifties of the previous century, physicians – who were treating patients suffering from a lead poisoning – discovered that their patients were having less heart complaints.

Personally, I have been using chelation in my practice for more than twenty years. The therapy has no side effects. I have administered over one thousand infusions and have experienced that the therapy works extremely well for clogged blood vessels in the legs and the heart area.

Over the past twenty years, chelation therapy has been the focus point of many scientific research, hereby inventorying its function and beneficial effects.  In 1993, a study was published that demonstrated that patients, who have suffered from a hearth attack and have afterwards undergone chelation therapy, were much less at risk of having another heart attack. Seventy percent were completely free of symptoms after three years and their quality of life had considerably improved: they found it easier to climb stairs, were less quickly out of breath, had a better blood circulation to the lower limbs, had less pain in the legs etc.

Research from 2014 (double-blind, placebo controlled) has shown that EDTA chelation therapy is indeed functioning well.
Especially diabetics benefit from it. These patients are very often subjected to cardiovascular disorders resulting from their disease.  Among diabetic patients, one has observed a decrease of 43 percent in mortality, relapse after operation and readmission at the hospital for heart problems. The recurrence of cardiovascular diseases had dropped with 18 percent in other patients.

Chelation therapy can also be used to prevent arteriosclerosis. It can be administered after a bypass operation to prevent recurrent heart attacks. In many cases, chelation therapy is a safe alternative for a heart operation and the therapy mostly succeeds in preventing operations of clogged blood vessels in the legs. Often, an amputation or heart operation can be prevented due to chelation therapy.

In my opinion, chelation therapy is a very valuable supplementary therapy, as part of a comprehensive treatment in which healthy nutrition, physical exercise, food supplements and reducing stress are also of great importance.  The therapy is also proving its value in supplementing classical medicine.

Chelation therapy influences two processes and thus works in two ways:

  1. EDTA neutralizes free radicals. If free radicals, influenced by certain circumstances (smoking, stress, unhealthy diet, air pollution, excessive alcohol consumption, certain medication), develop freely, they start damaging cells, which leads to an accelerated ageing process, cancer and arteriosclerosis. Heavy metals in the blood circulation can contribute to the production and activity of these free radicals. Chelation therapy ensures that heavy metals are eliminated.
  2. EDTA does not only bond with heavy metals, but also with calcium. This has a positive effect on the ratio between calcium and magnesium. It is also favorable for the process of arteriosclerosis.

In practice, the active substance EDTA is administered intravenously together with a cocktail of vitamins, minerals and amino acids. The treatment occurs once or twice a week and should be repeated twenty to fifty times, depending on the indication.



Chelation therapy to treat atherosclerosis, particularly in diabetes: is it time to reconsider?

Lamas GA, Ergui I.
Expert Rev Cardiovasc Ther. 2016 Aug;14(8):927-38. doi: 10.1080/14779072.2016.1180977. Epub 2016 May 5.

The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT).

Ujueta F, Arenas IA, Escolar E, Diaz D, Boineau R, Mark DB, Golden P, Lindblad L, Kim H, Lee KL, Lamas GA.
J Diabetes Complications. 2019 Jul;33(7):490-494. doi: 10.1016/j.jdiacomp.2019.04.005. Epub 2019 Apr

EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy.

Lamas GA, Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M, Rozema T, Nahin RL, Terry Chappell L, Lindblad L, Lewis EF, Drisko J, Lee KL.
Am Heart J. 2014 Jul;168(1):37-44.e5. doi: 10.1016/j.ahj.2014.02.012. Epub 2014 Apr 2.

Chelation therapy after the trial to assess chelation therapy: results of a unique trial.

Avila MD, Escolar E, Lamas GA.
Curr Opin Cardiol. 2014 Sep;29(5):481-8. doi: 10.1097/HCO.0000000000000096.

Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy.

Lamas GA, Navas-Acien A, Mark DB, Lee KL.
J Am Coll Cardiol. 2016 May 24;67(20):2411-2418. doi: 10.1016/j.jacc.2016.02.066.